The Center for Biosimilars® recaps the top stories for the week of September 30, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 30, 2019.
Number 5: A new report from the House Ways and Means Committee finds that Americans pay nearly 4 times more for drugs than do patients in other countries.
Number 4: During the week’s European Society for Medical Oncology Congress 2019, a research team presented findings from a phase 3 trial of Samsung Bioepis' proposed bevacizumab biosimilar.
Number 3: New research suggests that state-level drug price transparency laws are largely ineffective at revealing true transaction prices.
Number 2: A newly introduced item of legislation proposes to eliminate co-payments for patients when they receive biosimilars in Medicare Part B.
Number 1: Pfizer says that it will launch its bevacizumab biosimilar, Zirabev, in the United States on December 31.
Finally, last week, our e-newsletter asked whether you think that biosimilars of rituximab will make treatment more accessible for patients with neurological diseases like multiple sclerosis.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.